FDA approved BYOOVIZ as the first ophthalmology biosimilar, leading to a commercial rights transfer from Biogen to Harrow.
4 reports, 2 independent
Updated Jul 20
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved BYOOVIZ as the first ophthalmology biosimilar, leading to a commercial rights transfer from Biogen to Harrow.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Harrow Borough F.C.
association football club in Harrow, England
Nothing else this week.
-
Biogen
American multinational biotechnology company
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- manilatimes.net
- Business WireSamsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States Harrow will assume full commercial responsibility for BYOOVIZ®
- Business WireHarrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States Harrow to assume full commercial responsibility for BYOOVIZ® and OPUVI